白楊素( Chrysin )，被認為與許多疾病的生理機制及訊息傳遞路徑相關，但其呈疏水性且溶解度差與懸浮性不佳等特性，使其臨床應用受限。而聚縮酮( Polyketal ) 已用於包覆親、疏水性與蛋白質藥物運用於心血管、急性發炎與癌症等疾病之功能。故本研究將Chrysin與1,4-Cyclohexanedimethanol ( CDM )及2,2-Diethoxypropane ( DEP )合成為具抗發炎功效之聚縮酮( Polyketal )聚合物—PCADK-Chrysin，藉Chrysin增強聚縮酮抗發炎之功效。
第一階段，本實驗以不同比例之Chrysin與CDM合成數種新穎聚縮酮，其中Chrysin含量無法計算，分子量約為5600-12500 Dalton，裂解溫度120-195°C，且發現略減CDM之比例可提升分子量，其中PCADK-Chry.15%( CDM:DEP = 0.85：1 )組別分子量及裂解溫度較高。因此第二階段合成PCADK-CDM聚合物藉調整CDM及DEP比例，期以得到較高分子量之PCADK-CDM聚合物，藉此聚合物包覆Chrysin提高Chrysin含量，模擬PCADK-Chrysin NPs分析其抗發炎能力與細胞毒性。
第二階段，成功合成PCADK-CDM聚合物，其分子量及裂解溫度特性與PCADK-Chrysin趨勢相同，PCADK-CDM85%( CDM:DEP = 0.85：1 )組別分子量及裂解溫度較高，製備出之顆粒型態最完整，包埋率約為59.28%。
細胞實驗中，PCADK-CDM NPs 具有強烈奈米尺度毒性，Chrysin-PCADK-CDM NPs與純藥皆顯示未能抑制LPS所引起NO之釋放。

Chrysin, a natural anti-inflammatory compound, exhibits many beneficial effects. However, the hydrophobicity, low-solubility and poor-suspension properties of Chrysin have limited its clinical application.
In this study, we tried to solve the above problem by the following two methods: first, synthesis of a series of polymers containing Chrysin, and second, encapsulation of Chrysin into the polyketal nanoparticles.
In the first method, we synthesized several novel polyketal polymers based on different ratios of Chrysin and CDM. The results showed that the contents of Chrysin in these polymers can’t be calculated. The molecular weight of PCADK-Chrysin polymers ranges between 5600 and 12500 Dalton. The decomposition-temperature of PCADK-Chrysin were range between 120-195°C. Among these polymers, PCADK-Chrysin.15% ( CDM:DEP = 0.85：1 ) exhibit the highest decomposition-temperature and molecular weight.
In the second method, we synthesized PCADK-CDM with the same characteristic of PCADK-Chrysin. PCADK-CDM85%( CDM:DEP = 0.85：1 ) has the highest decomposition-temperature and molecular weight that can obtain the most completed nanoparticles. These PCADK-CDM NPs were used to encapsulate Chrysin, and the encapsulation efficiency is 59.28%.
However, the results in our in vitro test showed that PCADK-CDM NPs exhibited high cytotoxicity of nano-scale. Both Chrysin-PCADK-CDM NPs and the pure drug could not inhibit LPS induced NO production.

1. Aster, V.K.A.K.A.J.C., Robbins & Cotran Pathologic Basis of Disease, 9th Edition. 2015.
2. Hudson, J.D., et al., A proinflammatory cytokine inhibits p53 tumor suppressor activity. Journal of Experimental Medicine, 1999. 190(10): p. 1375-1382.
3. Coussens, L.M. and Z. Werb, Inflammation and cancer. Nature, 2002. 420(6917): p. 860-867.
4. Pietta, P.-G., Flavonoids as Antioxidants. J. Nat. Prod., 2000(63): p. 1035-1042.
5. Pushpavalli, G., et al., Effect of chrysin on hepatoprotective and antioxidant status in D-galactosamine-induced hepatitis in rats. Eur J Pharmacol, 2010. 631(1-3): p. 36-41.
6. Bae, Y., S. Lee, and S.H. Kim, Chrysin suppresses mast cell-mediated allergic inflammation: involvement of calcium, caspase-1 and nuclear factor-kappaB. Toxicol Appl Pharmacol, 2011. 254(1): p. 56-64.
7. Kasala, E.R., et al., Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives. Toxicol Lett, 2015. 233(2): p. 214-25.
8. Fiore, V.F., et al., Polyketal microparticles for therapeutic delivery to the lung. Biomaterials, 2010. 31(5): p. 810-817.
9. Leonardi, G.C., et al., Ageing: from inflammation to cancer. Immunity & Ageing, 2018. 15.
10. Watelet, J.B., et al., Chronic inflammation of upper airways in children: basic principles. B-Ent, 2012. 8: p. 29-40.
11. Wallace, G.R. and E. Niemczyk, Genetics in Ocular Inflammation-Basic Principles. Ocular Immunology and Inflammation, 2011. 19(1): p. 10-18.
12. Homey, B., A. Muller, and A. Zlotnik, Chemokines: Agents for the immunotherapy of cancer? Nature Reviews Immunology, 2002. 2(3): p. 175-184.
13. Scholl, S.M., et al., Anti-Colony-Stimulating Factor-I Antibody Staining in Primary Breast Adenocarcinomas Correlates with Marked Inflammatory Cell Infiltrates and Prognosis. Journal of the National Cancer Institute, 1994. 86(2): p. 120-126.
14. Maeda, H. and T. Akaike, Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry-Moscow, 1998. 63(7): p. 854-865.
15. Shacter, E. and S.A. Weitzman, Chronic inflammation and cancer. Oncology-New York, 2002. 16(2): p. 217-+.
16. Ernst, P.B. and B.D. Gold, The disease spectrum of Helicobacter pylori: The immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annual Review of Microbiology, 2000. 54: p. 615-640.
17. Kuper, H., H.O. Adami, and D. Trichopoulos, Infections as a major preventable cause of human cancer. Journal of Internal Medicine, 2000. 248(3): p. 171-183.
18. Kshirsagar, N.A., et al., Drug delivery systems (DDS) & biotechnology products: Clinical trials and regulatory requirements: Experience with product developed in India. Naunyn-Schmiedebergs Archives of Pharmacology, 1998. 358(1): p. R523-R523.
19. Freiberg, S. and X. Zhu, Polymer microspheres for controlled drug release. International Journal of Pharmaceutics, 2004. 282(1-2): p. 1-18.
20. Rajera, R., et al., Niosomes: A Controlled and Novel Drug Delivery System. Biological & Pharmaceutical Bulletin, 2011. 34(7): p. 945-953.
21. Chow, C.K.W., D.W. Matear, and H.P. Lawrence, Efficacy of antifungal agents in tissue conditioners in treating candidosis. Journal of Dental Research, 2000. 79: p. 377-377.
22. Sharma, P. and V. Hamsa, Formulation and evaluation of buccal mucoadhesive patches of terbutaline sulphate. Stp Pharma Sciences, 2001. 11(4): p. 275-281.
23. Rao, J.P. and K.E. Geckeler, Polymer nanoparticles: Preparation techniques and size-control parameters. Progress in Polymer Science, 2011. 36(7): p. 887-913.
24. Abhay N. Padalkar1*, S.R.S., Mahesh W. Thube1, Microparticles: an approach for betterment of drug delivery system. International Journal of Pharmaceutics, 2011. 3(1).
25. Toorisaka, E., et al., Hypoglycemic effect of surfactant-coated insulin solubilized in a novel solid-in-oil-in-water (S/O/W) emulsion. Int J Pharm, 2003. 252(1-2): p. 271-4.
26. Yang, S.C., et al., Polyketal copolymers: A new acid-sensitive delivery vehicle for treating acute inflammatory diseases. Bioconjugate Chemistry, 2008. 19(6): p. 1164-1169.
27. Yang, S.C., et al., Polyketal copolymers: a new acid-sensitive delivery vehicle for treating acute inflammatory diseases. Bioconjug Chem, 2008. 19(6): p. 1164-9.
28. Sy, J.C., et al., Sustained release of a p38 inhibitor from non-inflammatory microspheres inhibits cardiac dysfunction. Nature Materials, 2008. 7(11): p. 863-869.
29. Lee, S., et al., Polyketal microparticles: a new delivery vehicle for superoxide dismutase. Bioconjug Chem, 2007. 18(1): p. 4-7.
30. Wang, Y., B. Chang, and W. Yang, pH-sensitive polyketal nanoparticles for drug delivery. J Nanosci Nanotechnol, 2012. 12(11): p. 8266-75.
31. Bajgai, S.P., et al., Hybrid flavan-chalcones, aromatase and lipoxygenase inhibitors, from Desmos cochinchinensis. Phytochemistry, 2011. 72(16): p. 2062-7.
32. Escuredo, O., et al., Assessing Rubus honey value: Pollen and phenolic compounds content and antibacterial capacity. Food Chemistry, 2012. 130(3): p. 671-678.
33. Mamadalieva, N.Z., et al., Flavonoids in Scutellaria immaculata and S. ramosissima (Lamiaceae) and their biological activity. J Pharm Pharmacol, 2011. 63(10): p. 1346-57.
34. Mouffok, S., et al., Chemical constituents of Centaurea omphalotricha Coss. & Durieu ex Batt. & Trab. Records of Natural Products, 2012. 6(3): p. 292-295.
35. Pasini, F., et al., Buckwheat honeys: screening of composition and properties. Food Chem, 2013. 141(3): p. 2802-11.
36. Pereira, O.R., et al., Identification of phenolic constituents of Cytisus multiflorus. Food Chemistry, 2012. 131(2): p. 652-659.
37. Anitha, T.A. and M. Rajadurai, Antioxidative potential of chrysin, a flavone in streptozotocin–nicotinamide-induced diabetic rats. Biomedicine & Preventive Nutrition, 2014. 4(4): p. 511-517.
38. Zhou, L., et al., Solubility of Chrysin in Ethanol and Water Mixtures. Journal of Chemical and Engineering Data, 2014. 59(7): p. 2215-2220.
39. Ha, S.K., E. Moon, and S.Y. Kim, Chrysin suppresses LPS-stimulated proinflammatory responses by blocking NF-kappaB and JNK activations in microglia cells. Neurosci Lett, 2010. 485(3): p. 143-7.
40. Lim, H.K., et al., Chrysin Increases the Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema. Integr Cancer Ther, 2016.
41. Zhang, S., X. Yang, and M.E. Morris, Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol, 2004. 65(5): p. 1208-16.
42. Cardenas, M., et al., Antitumor activity of some natural flavonoids and synthetic derivatives on various human and murine cancer cell lines. Bioorganic & Medicinal Chemistry, 2006. 14(9): p. 2966-2971.
43. Wang, H.W., et al., Reversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin. Int J Cancer, 2007. 120(9): p. 2019-27.
44. Prangsaengtong, O., et al., Chrysin Inhibits Lymphangiogenesis in Vitro. Biol Pharm Bull, 2016. 39(4): p. 466-72.
45. Wolfman, C., et al., Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacol Biochem Behav, 1994. 47(1): p. 1-4.
46. Izuta, H., et al., Protective effects of Chinese propolis and its component, chrysin, against neuronal cell death via inhibition of mitochondrial apoptosis pathway in SH-SY5Y cells. J Agric Food Chem, 2008. 56(19): p. 8944-53.
47. Souza, L.C., et al., Flavonoid Chrysin prevents age-related cognitive decline via attenuation of oxidative stress and modulation of BDNF levels in aged mouse brain. Pharmacol Biochem Behav, 2015. 134: p. 22-30.
48. Filho, C.B., et al., Chronic unpredictable mild stress decreases BDNF and NGF levels and Na(+),K(+)-ATPase activity in the hippocampus and prefrontal cortex of mice: antidepressant effect of chrysin. Neuroscience, 2015. 289: p. 367-80.
49. Medina, J.H., et al., Chrysin (5,7-di-OH-flavone), a naturally-occurring ligand for benzodiazepine receptors, with anticonvulsant properties. Biochem Pharmacol, 1990. 40(10): p. 2227-31.
50. Kandhare, A.D., et al., Evaluation of the neuroprotective effect of chrysin via modulation of endogenous biomarkers in a rat model of spinal cord injury. J Nat Med, 2014. 68(3): p. 586-603.
51. 周俊良, 以大鼠急性肺損傷模式評估包覆厚朴酚微奈米顆粒之抗發炎能力. 醫學工程研究所, 2014(國立台灣科技大學): p. 台北市.
52. Schievano, E., et al., An NMR-based metabolomic approach to identify the botanical origin of honey. Metabolomics, 2012. 8(4): p. 679-690.
53. Toneli, A.E., NMR Spectroscopy and Polymer Microstructure The Conformational Connection. 1989. 252.
54. Oh, W.K., et al., Fluorescent polymer nanoparticle for selective sensing of intracellular hydrogen peroxide. ACS Nano, 2012. 6(10): p. 8516-24.
55. Zheng, S., et al., Sensitive fluorescence-based method for the rapid determination of polysorbate-80 content in therapeutic monoclonal antibody products. Pharm Dev Technol, 2014: p. 1-5.
56. Lee, J.Y. and W. Park, Anti-inflammatory effect of chrysin on RAW 264.7 mouse macrophages induced with polyinosinic-polycytidylic acid. Biotechnology and Bioprocess Engineering, 2015. 20(6): p. 1026-1034.
57. Lyu, S.Y. and W.B. Park, Production of cytokine and NO by and PBMC in vitro incubation with RAW 264.7 macrophages flavonoids. Archives of Pharmacal Research, 2005. 28(5): p. 573-581.